Diffuse cutaneous systemic sclerosis

This early-phase trial is testing an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the therapy might h…

This study tests an experimental drug called MTX-474 in 85 people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and organ damage. Participants will receive either MTX-474 or a placebo for 24 weeks to see if the drug safely reduces skin thickne…

This study tests whether the drug ianalumab can help people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and can damage internal organs like the lungs. About 200 adults will receive either ianalumab or a placebo as a shot under the skin. Rese…

This early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…

This early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically…

This early-stage trial tests an experimental cell therapy called NEUK203-215 in adults aged 18-65 with severe autoimmune diseases like lupus or scleroderma that have not responded to other treatments. The therapy uses immune cells from a healthy donor, engineered to target and at…

This early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…

This study tests whether adding two immune-targeting drugs (belimumab and rituximab) to standard mycophenolate can improve skin fibrosis in people with early diffuse systemic sclerosis. Thirty adults with recent-onset disease will receive either the combo or placebo injections fo…

This early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…

This study is testing a new, non-invasive imaging technique called spatial frequency domain imaging (SFDI) to measure skin thickness in people with scleroderma. Currently, doctors use a subjective pinch test, but SFDI uses light scattering to measure collagen in the skin more acc…